Adt

As part of the 2022 Prostate Cancer Patient Conference, Dr. Eric Small discusses androgen deprivation therapy and prostate cancer.

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer (2022) Jessica Delgado, Jesse Ory, Justin Loloi, Nicholas A. Deebel, Ari Bernstein, Sirpi Nackeeran, Isaac Zucker, Ranjith Ramasamy Abstract Introduction Many men receiving temporary...

Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy (2022) Julie Abildgaard, Hein Vincent Stroomberg, A Kirstine Bang, Jakob Albrethsen, Laura Smedegaard Kruuse, Anders Juul, Klaus Brasso, Andreas Røder, and Niels Jørgensen Abstract Men with high-risk...

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question (2022) Irene Caramella ● Alberto Dalla Volta ● Marco Bergamini ● Deborah Cosentini ● Francesca Valcamonico ● Alfredo Berruti Abstract...

In this 12-minute presentation, Mark A. Moyad, MD, MPH, interviews Celestia S. Higano, MD, FACP, about the importance of dual-energy X-ray absorptiometry (DEXA) screening to preserve bone health in men initiating androgen deprivation therapy (ADT).

Testosterone (T) Recovery Profiles After Short-Term Androgen Deprivation Therapy (ADT) (2022) JFlores Martinez, BNascimento, NBenfante, ESchofield, JPMulhall Introduction ADT plays a major role in several scenarios for men with prostate cancer. T recovery after ADT cessation may be incomplete...

Introduction Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer (2022) JDelgado, JOry, JBitran, RBlachman Braun ,SNackeeran, RRamasam Introduction ADT plays a fundamental role in the treatment of localized prostate cancer...